Back in February, the US Council of Economic Advisers issued a white paper on drug pricing implying that other rich countries should stop “free riding” off American innovation by negotiating drug prices to unfairly low levels after the US fronts the research and development costs. Perhaps in response, President Trump recently announced a proposal to bring down US drug prices. But until the US corrects the structural flaws in its own healthcare system, these efforts are bound to fall short.
Tag: The Trump Administration and Development
CGD experts are closely monitoring what the change in leadership in the United States portends for US development policy. Watch this space for detailed analysis of the new administration’s actions.